Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tretinoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 5/20 | 1.00 |
| ▸ | RARA known ✓ | P10276 | 4/20 | 1.00 |
| ▸ | RARB known ✓ | P10826 | 4/20 | 1.00 |
| ▸ | RARG known ✓ | P13631 | 4/20 | 1.00 |
| ▸ | RXRB known ✓ | P28702 | 2/20 | 1.00 |
| ▸ | RXRG known ✓ | P48443 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | RORC | P51449 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tretinoin SCHEMBL942726 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL12494390 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL4321428 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982760 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL9856240 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982761 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL5324134 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL13238976 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL20603086 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL3952 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736865-B2 | Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle | RETINAGENIX THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190183835-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE | ELUMINEX BIOSCIENCES (SUZHOU) LIMITED (CN) | 2019-06-20 | — | — | US | disclosed |
| US-10130606-B2 | Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle | NOVELION THERAPEUTICS INC. (CA) | 2018-11-20 | — | — | US | disclosed |
| US-9572815-B2 | Methods and compositions of p27KIP1 transcriptional modulators | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170007565-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE | ELUMINEX BIOSCIENCES (SUZHOU) LIMITED (CN) | 2017-01-12 | — | — | US | disclosed |
| US-20160030445-A1 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-02-04 | — | — | US | disclosed |
| US-20120178806-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE | QLT INC. (CA) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183835-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE | RBP4, LRAT, RARG | RXRA 6/4885RARA 5/4885RARB 7/4885 |
| US-20120178806-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE | RBP4, LRAT, RARG | RXRA 6/4885RARA 5/4885RARB 7/4885 |
| US-10130606-B2 | Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle | RBP4, LRAT, RARG | RXRA 6/4885RARA 5/4885RARB 7/4885 |
| US-20170007565-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE | RBP4, LRAT, RARG | RXRA 6/4885RARA 5/4885RARB 7/4885 |
| US-20160030445-A1 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS | WNT1, CTNNB1, CTNNBL1 | RXRA 1872/4885RARA 1684/4885RARB 903/4885 |
| US-10736865-B2 | Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle | RBP4, LRAT, RARG | RXRA 6/4885RARA 5/4885RARB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.